Dr Jonathan Silverberg, from George Washington University in Washington, DC, offers insight on key findings on atopic dermatitis presented at the AAD Summer Meeting 2021.
First, he discusses a study that found that the families of children with severe atopic dermatitis treated with dupilumab had significant improvements in their quality of life.
Next, Dr Silverberg analyzes a study that looked at dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis. It shows that the mechanism of dupilumab may inadvertently activate the Th1 and Th17 pathways implicated in psoriasis pathogenesis.
He then discusses an analysis that looks at cutaneous T-cell lymphoma development after biologic therapy and the takeaway physicians should consider when diagnosing severe inflammatory skin diseases, such as atopic dermatitis.
Finally, he highlights emerging agents in biologic, oral, and topical therapies examined by studies presented at the meeting.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Atopic Dermatitis Highlights From AAD Summer Meeting 2021 - Medscape - Aug 25, 2021.
Comments